ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery AUSTIN, Texas—ImmunoPrecise Antibodies Ltd. (IPA), a prominent player in AI-driven biotherapeutics, has announced a significant discovery using its proprietary LENSai™ platform, powered by HYFT® technology. The company identified a highly conserved epitope—a specific part of the virus—that is present across all four dengue virus serotypes. This unprecedented achievement opens doors to the development of a universal dengue vaccine, a goal that has eluded scientists for decades. The Challenge of a Universal Dengue Vaccine Dengue fever, caused by four distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), is a major global health issue. Infection with one serotype does not confer immunity to the others and can even exacerbate subsequent infections. This complexity has made developing a broadly protective vaccine extremely difficult. Traditional methods of vaccine discovery, whether experimental or computational, have struggled to identify a viral component that remains exposed and conserved across all serotypes. The Breakthrough Discovery ImmunoPrecise Antibodies employed its LENSai™ platform, which integrates deep learning, structural predictions, and literature-mined knowledge graphs, to identify the conserved epitope. The platform's patented HYFT® technology allows for the mapping of biologically meaningful sub-sequence patterns across the entire biosphere, ensuring comprehensive and precise analysis. This in silico approach, which relies solely on computational models, demonstrated remarkable efficiency in translating complex biological data into actionable vaccine design, bypassing the time-consuming and resource-intensive traditional trial-and-error methods. Key Features of LENSai™ and HYFT® Technology The LENSai™ platform is designed to accelerate the drug discovery process by leveraging advanced AI models. HYFT® technology, specifically, excels in identifying universal fingerprints within sequences, which are crucial for recognizing conserved biological structures. By confirming that these sequence-derived patterns match structural signatures across all dengue serotypes, IPA has set a new standard in computational vaccinology. This method not only saves time and reduces costs but also provides deeper insights into viral targets, making it easier to design vaccines that are effective against multiple strains of the virus. Implications Beyond Dengue The success of IPA’s AI-driven platform in the dengue vaccine discovery has far-reaching implications. The company plans to extend its capabilities to other high-impact infectious diseases such as HIV, Norovirus, and RSV. Early-stage assessments are also being conducted to explore the platform's potential in oncology, particularly for neoantigen vaccine development and tumor-specific epitope mapping. This versatility underscores the platform's applicability to a wide range of medical challenges, positioning IPA as a frontrunner in the field of AI-native drug discovery. Advancing Drug Discovery and Vaccine Development ImmunoPrecise Antibodies' commitment to advancing drug discovery through human-relevant AI technologies is evident in this breakthrough. Their integrated suite of capabilities, including multi-omics modeling, supports the development of therapeutic antibodies and addresses complex industry challenges. The company has several subsidiaries in North America and Europe, collectively enhancing its global reach and impact. Industry Insights and Evaluation Industry experts commend IPA’s innovative approach, noting that the integration of AI with deep biological understanding is crucial for addressing stubborn medical challenges. Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, highlighted the significance of this discovery: "This breakthrough represents a paradigm shift in how we approach vaccine development. By identifying a persistent target across all dengue serotypes, we are laying the groundwork for more efficient and effective vaccine designs, which can potentially be applied to other diseases and even cancers." Company Profile ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a leading techbio company headquartered in Austin, Texas. Known for its pioneering work in AI-driven drug discovery, IPA utilizes a range of proprietary and patented technologies to support the development of therapeutic antibodies. The company’s comprehensive capabilities and strategic global presence position it at the forefront of the biotherapeutics industry. Forward-Looking Statements This press release includes forward-looking statements related to the anticipated benefits, scalability, adoption, and broader application of IPA's LENSai™ and HYFT® platforms. Readers are cautioned that these statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual outcomes to differ significantly. Factors include scientific and technological developments, changes in regulatory requirements, competitive dynamics, and economic conditions. For more detailed information, refer to the Company’s Annual Report on Form 20-F.